Related Experiment Video

Updated: Mar 20, 2026

A Rat Tibial Growth Plate Injury Model to Characterize Repair Mechanisms and Evaluate Growth Plate Regeneration Strategies
06:53

A Rat Tibial Growth Plate Injury Model to Characterize Repair Mechanisms and Evaluate Growth Plate Regeneration Strategies

Published on: July 4, 2017

11.8K

Zoledronate for Osteogenesis imperfecta: evaluation of safety profile in children

Chanchal Kumar, Inusha Panigrahi, Abhishek Somasekhara Aradhya

    Journal of Pediatric Endocrinology & Metabolism : JPEM
    |May 29, 2016
    PubMed

    Insights

    Zoledronate is effective in reducing fractures in children with Osteogenesis imperfecta (OI). While short-term reactions occurred, no long-term side effects like osteonecrosis of the jaw were observed in this study.

    Area of Science:

    • Pediatric Endocrinology
    • Skeletal Dysplasias
    • Pharmacology

    Background:

    • Bisphosphonates (BPs) have transformed Osteogenesis imperfecta (OI) treatment.
    • Zoledronate use in OI has raised safety concerns due to limited research.
    • This study retrospectively analyzes zoledronate's safety and fracture frequency in pediatric OI patients.

    Purpose of the Study:

    • To evaluate the short- and long-term side effects of zoledronate in children with OI.
    • To assess the impact of zoledronate on fracture frequency in pediatric OI patients.

    Main Methods:

    • Retrospective analysis of 26 children diagnosed with OI.
    • Zoledronate administered cyclically for a median of 36 months.
    • Safety assessment included short- and long-term effects and fracture rates.

    Main Results:

    • One neonate (3%) experienced symptomatic hypocalcemia post-infusion.
    • Three children (11%) exhibited acute phase reactions.
    • No long-term side effects, including osteonecrosis of the jaw, were observed over 7 years. Significant fracture reduction occurred in OI types III and IV (p<0.05).

    Conclusions:

    • Zoledronate demonstrated efficacy in reducing fractures in OI types III and IV.
    • Short-term adverse events were manageable.
    • Longer-duration studies are needed to confirm the long-term safety profile of zoledronate in OI.
    Abstract

    More Related Videos

    Proper Positioning and Restraint of a Rat Hind Limb for Focused High Resolution Imaging of Bone Micro-architecture Using In Vivo Micro-computed Tomography04:24

    Proper Positioning and Restraint of a Rat Hind Limb for Focused High Resolution Imaging of Bone Micro-architecture Using In Vivo Micro-computed Tomography

    Published on: November 22, 2017

    10.4K
    Analysis of Minerals Produced by hFOB 1.19 and Saos-2 Cells Using Transmission Electron Microscopy with Energy Dispersive X-ray Microanalysis14:55

    Analysis of Minerals Produced by hFOB 1.19 and Saos-2 Cells Using Transmission Electron Microscopy with Energy Dispersive X-ray Microanalysis

    Published on: June 24, 2018

    9.8K

    Related Concept Videos

    Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

    Pharmacokinetics in Pediatric Patients: Drug Metabolism

    In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
    315
    Bone Disorders01:29

    Bone Disorders

    Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
    Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
    6.4K
    Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

    Pharmacokinetics in Pediatric Patients: Drug Distribution

    Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
    439
    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

    Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

    Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
    664
    Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

    Pharmacokinetics in Pediatric Patients: Drug Excretion

    In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
    368
    Drug Dosing: Infants and Children01:29

    Drug Dosing: Infants and Children

    Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
    705